Wagering on Unfinished Experiments—Prediction Markets and Clinical Trial Integrity
JAMA · 29.10.2026
DOI: 10.1001/jama.2026.19361 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, online erschienen am 29.10.2026. Verfasst von Jay B Lusk und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Texas Southwestern Medical Center, Dallas. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
This Viewpoint discusses the potential impact on recruitment, retention, measurement, or evidence generation after a prediction market platform announced it would host betting on the outcomes of clinical trials and US Food and Drug Administration regulatory reviews, noting that policy action is needed to ensure that prediction markets do not undermine the public interest.
Autor:innen und Institutionen
- Department of Neurology, University of Texas Southwestern Medical Center, Dallas.
- Duke Clinical Research Institute, Durham, North Carolina.
- Department of Medicine, University of Texas Southwestern Medical Center, Dallas.
Zitieren
APA
Lusk, J. B., Califf, R. M., Navar, A. M., & O'Brien, E. C. (2026). Wagering on Unfinished Experiments—Prediction Markets and Clinical Trial Integrity. JAMA. https://doi.org/10.1001/jama.2026.19361
Vancouver
Lusk JB, Califf RM, Navar AM, O'Brien EC. Wagering on Unfinished Experiments—Prediction Markets and Clinical Trial Integrity. JAMA. 2026. doi:10.1001/jama.2026.19361
BibTeX
@article{Lusk2026,
author = {Lusk, Jay B and Califf, Robert M and Navar, Ann Marie and O'Brien, Emily C},
title = {Wagering on Unfinished Experiments—Prediction Markets and Clinical Trial Integrity},
journal = {JAMA},
year = {2026},
doi = {10.1001/jama.2026.19361}
}
EUVIMED